Role of long term antibiotics in chronic respiratory diseases

Respiratory Medicine

Volumn 107, Issue 6, 2013, Pages 800-815

  Suresh Babu, K ^a   Kastelik, J ^b   Morjaria, J B ^b  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Asthma; Bronchiectasis; COPD; Cystic fibrosis; Macrolides

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; ERYTHROMYCIN; GENTAMICIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MOXIFLOXACIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PLACEBO; ROXITHROMYCIN; TAUROLIDINE; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ANTIBIOTIC THERAPY; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LOW DRUG DOSE; NEBULIZATION; POST TRANSPLANT BRONCHIOLITIS OBLITERANS SYNDROME; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ASTHMA; BRONCHIECTASIS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; MACROLIDES; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 84877580620     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.02.009     Document Type: Review

References (134)

1. M.T. Labro Cellular and molecular effects of macrolides on leukocyte function Curr Pharm Des 10 25 2004 3067 3080
2. A.L. Friedlander, and R.K. Albert Chronic macrolide therapy in inflammatory airways diseases Chest 138 5 2010 Nov 1202 1212
3. B.K. Rubin, and M.O. Henke Immunomodulatory activity and effectiveness of macrolides in chronic airway disease Chest 125 2 Suppl. 2004 Feb 70S 78S
4. M. Yang, B.R. Dong, J. Lu, X. Lin, and H.M. Wu Macrolides for diffuse panbronchiolitis Cochrane Database Syst Rev 12 2010 CD007716
5. T. Koyama, H. Takizawa, S. Kawasaki, K. Takami, T. Otoshi, and K. Ito Effects of various drugs on IL-8 production by eosinophils collected from patients with allergic inflammation Jpn J Antibiot 51 Suppl. A 1998 Jan 131 133
6. L. Richeldi, G. Ferrara, L.M. Fabbri, T.J. Lasserson, and P.G. Gibson Macrolides for chronic asthma Cochrane Database Syst Rev 4 2005 CD002997
7. B. Hrvacic, B. Bosnjak, M. Bosnar, Z. Ferencic, I. Glojnaric, and V. Erakovic Haber Clarithromycin suppresses airway hyperresponsiveness and inflammation in mouse models of asthma Eur J Pharmacol 616 1-3 2009 Aug 15 236 243
8. Y. Morinaga, K. Yanagihara, N. Miyashita, M. Seki, K. Izumikawa, and H. Kakeya Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells Pulm Pharmacol Ther 22 6 2009 Dec 580 586
9. M. Fonseca-Aten, P.J. Okada, K.L. Bowlware, S. Chavez-Bueno, A. Mejias, and A.M. Rios Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial Ann Allergy Asthma Immunol 97 4 2006 Oct 457 463
10. Y. Kaneko, K. Yanagihara, M. Seki, M. Kuroki, Y. Miyazaki, and Y. Hirakata Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis Am J Physiol Lung Cell Mol Physiol 285 4 2003 Oct L847 L853
11. S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, and M. Holmes Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease Am J Respir Crit Care Med 178 2 2008 Jul 15 139 148
12. S. Hodge, and P.N. Reynolds Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects Respirology 17 5 2012 Jul 802 807
13. R.J. Gillis, and B.H. Iglewski Azithromycin retards Pseudomonas aeruginosa biofilm formation J Clin Microbiol 42 12 2004 Dec 5842 5845 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
14. Y. Nalca, L. Jansch, F. Bredenbruch, R. Geffers, J. Buer, and S. Haussler Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach Antimicrob Agents Chemother 50 5 2006 May 1680 1688 [Comparative Study Research Support, Non-U.S. Gov't]
15. D.G. Peckham Macrolide antibiotics and cystic fibrosis Thorax 57 3 2002 Mar 189 190
16. K. Terada, S. Muro, S. Sato, T. Ohara, A. Haruna, and S. Marumo Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation Thorax 63 11 2008 Nov 951 955
17. K. Blondeau, L.J. Dupont, V. Mertens, G. Verleden, A. Malfroot, and Y. Vandenplas Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis Gut 57 8 2008 Aug 1049 1055
18. V. Mertens, K. Blondeau, A. Pauwels, R. Farre, B. Vanaudenaerde, and R. Vos Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients Dig Dis Sci 54 5 2009 May 972 979
19. T. Kohyama, Y. Yamauchi, H. Takizawa, S. Itakura, S. Kamitani, and J. Kato Clarithromycin inhibits fibroblast migration Respir Med 102 12 2008 Dec 1769 1776
20. M. Shinkai, J. Tamaoki, H. Kobayashi, S. Kanoh, K. Motoyoshi, and T. Kute Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression Antimicrob Agents Chemother 50 5 2006 May 1738 1744
21. M. Renna, C. Schaffner, K. Brown, S. Shang, M.H. Tamayo, and K. Hegyi Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection J Clin Invest 121 9 2011 Sep 3554 3563
22. A.L. Roux, E. Catherinot, F. Ripoll, N. Soismier, E. Macheras, and S. Ravilly Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france J Clin Microbiol 47 12 2009 Dec 4124 4128
23. C.R. Esther Jr., D.A. Esserman, P. Gilligan, A. Kerr, and P.G. Noone Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis J Cyst Fibros 9 2 2010 Mar 117 123
24. Cystic Fibrosis Foundation Trust Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Trust Antibiotic Working Group Foundation patient registry 2008 annual data report 2009 London, UK
25. J.A. Kastelik, G.A. Wright, I. Aziz, M. Davies, G.R. Avery, and A.J. Paddon A widely available method for the assessment of aerosol delivery in cystic fibrosis Pulm Pharmacol Ther 15 6 2002 513 519
26. H. Heijerman, E. Westerman, S. Conway, D. Touw, and G. Doring Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus J Cyst Fibros 8 5 2009 Sep 295 315
27. G. Latchford, A. Duff, J. Quinn, S. Conway, and M. Conner Adherence to nebulised antibiotics in cystic fibrosis Patient Educ Couns 75 1 2009 Apr 141 144
28. D.R. Rollins, D.A. Beuther, and R.J. Martin Update on infection and antibiotics in asthma Curr Allergy Asthma Rep 10 1 2010 Jan 67 73
29. D.A. Fost, D.Y. Leung, R.J. Martin, E.E. Brown, S.J. Szefler, and J.D. Spahn Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy J Allergy Clin Immunol 103 6 1999 Jun 1031 1035
30. J.D. Spahn, D.A. Fost, R. Covar, R.J. Martin, E.E. Brown, and S.J. Szefler Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study Ann Allergy Asthma Immunol 87 6 2001 Dec 501 505
31. A. Jaffe, and A. Bush Anti-inflammatory effects of macrolides in lung disease Pediatr Pulmonol 31 6 2001 Jun 464 473
32. S.J. Szefler, J.Q. Rose, E.F. Ellis, S.L. Spector, A.W. Green, and W.J. Jusko The effect of troleandomycin on methylprednisolone elimination J Allergy Clin Immunol 66 6 1980 Dec 447 451
33. A. Ekici, M. Ekici, and A.K. Erdemoglu Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma J Asthma 39 2 2002 Apr 181 185
34. T. Shimizu, M. Kato, H. Mochizuki, K. Tokuyama, A. Morikawa, and T. Kuroume Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma Chest 106 2 1994 Aug 458 461
35. K.S. Babu, D.E. Davies, and S.T. Holgate Role of tumor necrosis factor alpha in asthma Immunol Allergy Clin North Am 24 4 2004 Nov 583 597 [v-vi]
36. J.B. Morjaria, K.S. Babu, P. Vijayanand, A.J. Chauhan, D.E. Davies, and S.T. Holgate Sputum IL-6 concentrations in severe asthma and its relationship with FEV1 Thorax 66 6 2011 Jun 537
37. I.H. Itkin, and M.L. Menzel The use of macrolide antibiotic substances in the treatment of asthma J Allergy 45 3 1970 Mar 146 162
38. S.L. Spector, F.H. Katz, and R.S. Farr Troleandromycin: effectiveness in steroid-dependent asthma and bronchitis J Allergy Clin Immunol 54 6 1974 367 379
39. B.D. Ball, M.R. Hill, M. Brenner, R. Sanks, and S.J. Szefler Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children Ann Allergy 65 1 1990 Jul 37 45
40. H. Amayasu, S. Yoshida, S. Ebana, Y. Yamamoto, T. Nishikawa, and T. Shoji Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma Ann Allergy Asthma Immunol 84 6 2000 Jun 594 598
41. P.N. Black, F. Blasi, C.R. Jenkins, R. Scicchitano, G.D. Mills, and A.R. Rubinfeld Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae Am J Respir Crit Care Med 164 4 2001 Aug 15 536 541
42. A.K. Kamada, M.R. Hill, D.N. Ikle, A.M. Brenner, and S.J. Szefler Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma J Allergy Clin Immunol 91 4 1993 Apr 873 882
43. E. Kostadima, S. Tsiodras, E.I. Alexopoulos, A.G. Kaditis, I. Mavrou, and N. Georgatou Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma Eur Respir J 23 5 2004 May 714 717
44. M. Kraft, G.H. Cassell, J. Pak, and R.J. Martin Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin Chest 121 6 2002 Jun 1782 1788
45. H.S. Nelson, D.L. Hamilos, P.R. Corsello, N.V. Levesque, A.D. Buchmeier, and B.L. Bucher A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids Am Rev Respir Dis 147 2 1993 Feb 398 404
46. T. Shoji, S. Yoshida, H. Sakamoto, H. Hasegawa, H. Nakagawa, and H. Amayasu Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma Clin Exp Allergy 29 7 1999 Jul 950 956
47. J.L. Simpson, H. Powell, M.J. Boyle, R.J. Scott, and P.G. Gibson Clarithromycin targets neutrophilic airway inflammation in refractory asthma Am J Respir Crit Care Med 177 2 2008 Jan 15 148 155
48. E.F. Juniper, G.H. Guyatt, P.J. Ferrie, and L.E. Griffith Measuring quality of life in asthma Am Rev Respir Dis 147 4 1993 Apr 832 838
49. G.L. Piacentini, D.G. Peroni, A. Bodini, R. Pigozzi, S. Costella, and A. Loiacono Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report Allergy Asthma Proc 28 2 2007 Mar-Apr 194 198
50. D.L. Hahn, M.B. Plane, O.S. Mahdi, and G.I. Byrne Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma PLoS Clin Trial 1 2 2006 Jun e11
51. L.C. Price, D. Lowe, H.S. Hosker, K. Anstey, M.G. Pearson, and C.M. Roberts UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation Thorax 61 10 2006 Oct 837 842 [Multicenter study]
52. J.J. Soler-Cataluna, M.A. Martinez-Garcia, P. Roman Sanchez, E. Salcedo, M. Navarro, and R. Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 11 2005 Nov 925 931
53. F.J. Martinez, J.L. Curtis, and R. Albert Role of macrolide therapy in chronic obstructive pulmonary disease Int J Chronic Obstructive Pulm Dis 3 3 2008 331 350 [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review]
54. J. Gomez, V. Banos, E. Simarro, M. Lorenzo Cruz, J. Ruiz Gomez, and J. Latour Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia 13 4 2000 Dec 379 383 [Clinical Trial Comparative Study Randomized Controlled Trial]
55. R.K. Albert, J. Connett, W.C. Bailey, R. Casaburi, J.A. Cooper Jr., and G.J. Criner Azithromycin for prevention of exacerbations of COPD N Engl J Med 365 8 2011 Aug 25 689 698 [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural]
56. D. Banerjee, O.A. Khair, and D. Honeybourne The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD Respir Med 99 2 2005 Feb 208 215 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]
57. S.S. Marcon, A.F. Rossini, and E.L. Aceti Nursing assistance by a home care team after the death of the patient Rev Bras Enferm 51 3 1998 Jul-Sep 379 392
58. Z.Y. He, L.M. Ou, J.Q. Zhang, J. Bai, G.N. Liu, and M.H. Li Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease Respiration 80 6 2010 445 452 [Randomized Controlled Trial Research Support, Non-U.S. Gov't]
59. T.A. Seemungal, T.M. Wilkinson, J.R. Hurst, W.R. Perera, R.J. Sapsford, and J.A. Wedzicha Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am J Respir Crit Care Med 178 11 2008 Dec 1 1139 1147 [Randomized Controlled Trial Research Support, Non-U.S. Gov't]
60. S. Sethi, P.W. Jones, M.S. Theron, M. Miravitlles, E. Rubinstein, and J.A. Wedzicha Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Respir Res 11 2010 10 [Randomized Controlled Trial Research Support, Non-U.S. Gov't]
61. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N Engl J Med 352 19 2005 May 12 1992 2001
62. B.P. O'Sullivan, and S.D. Freedman Cystic fibrosis Lancet 373 9678 2009 May 30 1891 1904
63. J.M. Rommens, M.C. Iannuzzi, B. Kerem, M.L. Drumm, G. Melmer, and M. Dean Identification of the cystic fibrosis gene: chromosome walking and jumping Science 245 4922 1989 Sep 8 1059 1065
64. M.J. Welsh Targeting the basic defect in cystic fibrosis N Engl J Med 363 21 2010 Nov 18 2056 2057
65. D. Bilton, G. Canny, S. Conway, S. Dumcius, L. Hjelte, and M. Proesmans Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials J Cyst Fibros 10 Suppl. 2 2011 Jun S79 S81
66. I.J. Clifton, J.A. Kastelik, D.G. Peckham, A. Hale, M. Denton, and C. Etherington Ten years of viral and non-bacterial serology in adults with cystic fibrosis Epidemiol Infect 136 1 2008 Jan 128 134
67. R.C. Boucher New concepts of the pathogenesis of cystic fibrosis lung disease Eur Respir J 23 1 2004 Jan 146 158
68. A. Smyth, and S. Walters Prophylactic antibiotics for cystic fibrosis Cochrane Database Syst Rev 3 2003 CD001912
69. A. Jaffe, J. Francis, M. Rosenthal, and A. Bush Long-term azithromycin may improve lung function in children with cystic fibrosis Lancet 351 9100 1998 Feb 7 420
70. J. Wolter, S. Seeney, S. Bell, S. Bowler, P. Masel, and J. McCormack Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial Thorax 57 3 2002 Mar 212 216
71. L. Saiman, B.C. Marshall, N. Mayer-Hamblett, J.L. Burns, A.L. Quittner, and D.A. Cibene Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial JAMA 290 13 2003 Oct 1 1749 1756
72. D. Nguyen, M.J. Emond, N. Mayer-Hamblett, L. Saiman, B.C. Marshall, and J.L. Burns Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes Pediatr Pulmonol 42 6 2007 Jun 533 541
73. A. Clement, A. Tamalet, E. Leroux, S. Ravilly, B. Fauroux, and J.P. Jais Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial Thorax 61 10 2006 Oct 895 902
74. K.W. Southern, P.M. Barker, and A. Solis Macrolide antibiotics for cystic fibrosis Cochrane Database Syst Rev 2 2004 CD002203
75. J. McCormack, S. Bell, S. Senini, K. Walmsley, K. Patel, and C. Wainwright Daily versus weekly azithromycin in cystic fibrosis patients Eur Respir J 30 3 2007 Sep 487 495
76. O.M. Pirzada, J. McGaw, C.J. Taylor, and M.L. Everard Improved lung function and body mass index associated with long-term use of macrolide antibiotics J Cyst Fibros 2 2 2003 Jun 69 71
77. C.R. Hansen, T. Pressler, C. Koch, and N. Hoiby Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study J Cyst Fibros 4 1 2005 Mar 35 40
78. S.K. Kabra, R. Pawaiya, R. Lodha, A. Kapil, M. Kabra, and A.S. Vani Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial J Cyst Fibros 9 1 2010 Jan 17 23
79. J.A. Kastelik, D.G. Peckham, and S. Conway Azithromycin in cystic fibrosis Eur Respir J 25 4 2005 Apr 771 author reply -2
80. J. Emerson, M. Rosenfeld, S. McNamara, B. Ramsey, and R.L. Gibson Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pediatr Pulmonol 34 2 2002 Aug 91 100
81. B. Frederiksen, C. Koch, and N. Hoiby Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis Pediatr Pulmonol 23 5 1997 May 330 335
82. N.H. Valerius, C. Koch, and N. Hoiby Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment Lancet 338 8769 1991 Sep 21 725 726
83. M.E. Hodson, C.G. Gallagher, and J.R. Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 20 3 2002 Sep 658 664
84. B.W. Ramsey, M.S. Pepe, J.M. Quan, K.L. Otto, A.B. Montgomery, and J. Williams-Warren Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N Engl J Med 340 1 1999 Jan 7 23 30
85. J.M. Littlewood, M.G. Miller, A.T. Ghoneim, and C.H. Ramsden Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis Lancet 1 8433 1985 Apr 13 865
86. N.R. Crowther Labiris, A.M. Holbrook, H. Chrystyn, S.M. Macleod, and M.T. Newhouse Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study Am J Respir Crit Care Med 160 5 Pt 1 1999 Nov 1711 1716
87. R.L. Gibson, G.Z. Retsch-Bogart, C. Oermann, C. Milla, J. Pilewski, and C. Daines Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Pediatr Pulmonol 41 7 2006 Jul 656 665
88. M.J. Ledson, M.J. Gallagher, M. Robinson, C. Cowperthwaite, T. Williets, and C.A. Hart A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia J Aerosol Med 15 1 2002 51 57 Spring
89. R.L. Gibson, J. Emerson, S. McNamara, J.L. Burns, M. Rosenfeld, and A. Yunker Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis Am J Respir Crit Care Med 167 6 2003 Mar 15 841 849
90. J.L. Burns, J.M. Van Dalfsen, R.M. Shawar, K.L. Otto, R.L. Garber, and J.M. Quan Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis J Infect Dis 179 5 1999 May 1190 1196
91. G. Ryan, M. Singh, and K. Dwan Inhaled antibiotics for long-term therapy in cystic fibrosis Cochrane Database Syst Rev 3 2011 CD001021
92. M.K. Daddario, J.K. Hagerman, and M.E. Klepser Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis Infect Drug Resist 3 2010 123 132
93. K.S. McCoy, A.L. Quittner, C.M. Oermann, R.L. Gibson, G.Z. Retsch-Bogart, and A.B. Montgomery Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis Am J Respir Crit Care Med 178 9 2008 Nov 1 921 928
94. G.Z. Retsch-Bogart, A.L. Quittner, R.L. Gibson, C.M. Oermann, K.S. McCoy, and A.B. Montgomery Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis Chest 135 5 2009 May 1223 1232
95. C.M. Oermann, G.Z. Retsch-Bogart, A.L. Quittner, R.L. Gibson, K.S. McCoy, and A.B. Montgomery An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis Pediatr Pulmonol 45 11 2010 Nov 1121 1134
96. D.E. Geller, P.A. Flume, D. Staab, R. Fischer, J.S. Loutit, and D.J. Conrad Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 11 2011 Jun 1 1510 1516
97. D. Bilton, D.J. Serisier, A.T. De Soyza, R. Wolfe, and P. Bruinenberg Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Eur Respir J 38 Suppl. 55 2011 333S
98. BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease Thorax 63 Suppl. 1 2008 Mar i1 i16 [Practice Guideline Review]
99. PROLONGED antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council Br Med J 2 5039 1957 Aug 3 255 259
100. D.C. Currie, N.D. Garbett, K.L. Chan, E. Higgs, H. Todd, and M.V. Chadwick Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis Q J Med 76 280 1990 Aug 799 816 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]
101. C. Wong, L. Jayaram, N. Karalus, T. Eaton, C. Tong, and H. Hockey Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial Lancet 380 9842 2012 Aug 18 660 667
102. G. Davies, and R. Wilson Prophylactic antibiotic treatment of bronchiectasis with azithromycin Thorax 59 6 2004 Jun 540 541 [Letter]
103. M.E. Drobnic, P. Sune, J.B. Montoro, A. Ferrer, and R. Orriols Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa Ann Pharmacother 39 1 2005 Jan 39 44 [Clinical Trial Randomized Controlled Trial]
104. M.P. Murray, J.R. Govan, C.J. Doherty, A.J. Simpson, T.S. Wilkinson, and J.D. Chalmers A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis Am J Respir Crit Care Med 183 4 2011 Feb 15 491 499
105. R. Orriols, J. Roig, J. Ferrer, G. Sampol, A. Rosell, and A. Ferrer Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa Respir Med 93 7 1999 Jul 476 480 [Clinical Trial Randomized Controlled Trial]
106. E. Yalcin, N. Kiper, U. Ozcelik, D. Dogru, P. Firat, and A. Sahin Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis J Clin Pharm Ther 31 1 2006 Feb 49 55 [Randomized Controlled Trial]
107. A.F. Barker, L. Couch, S.B. Fiel, M.H. Gotfried, J. Ilowite, and K.C. Meyer Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis Am J Respir Crit Care Med 162 2 Pt 1 2000 Aug 481 485 [Clinical Trial Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't]
108. M.C. Pasteur, D. Bilton, and A.T. Hill British Thoracic Society guideline for non-CF bronchiectasis Thorax 65 Suppl. 1 2010 Jul i1 58 [Practice Guideline Review]
109. H. Homma, A. Yamanaka, S. Tanimoto, M. Tamura, Y. Chijimatsu, and S. Kira Diffuse panbronchiolitis. A disease of the transitional zone of the lung Chest 83 1 1983 Jan 63 69
110. K. Ding, M.B. Liu, J.L. Wu, H.Q. Ma, X.Y. Fang, and G.B. Miao Diffuse panbronchiolitis in China: analysis of 45 cases Chin Med J (Engl) 120 22 2007 Nov 20 2046 2048
111. T. Izumi Diffuse panbronchiolitis Chest 100 3 1991 Sep 596 597
112. S. Kudoh, A. Azuma, M. Yamamoto, T. Izumi, and M. Ando Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 6 Pt 1 1998 Jun 1829 1832
113. S. Kudoh, T. Uetake, K. Hagiwara, M. Hirayama, L.H. Hus, and H. Kimura Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis Nihon Kyobu Shikkan Gakkai Zasshi 25 6 1987 Jun 632 642
114. J. Tamaoki, K. Takeyama, E. Tagaya, and K. Konno Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections Antimicrob Agents Chemother 39 8 1995 Aug 1688 1690
115. J. Kadota, H. Mukae, H. Ishii, T. Nagata, H. Kaida, and K. Tomono Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis Respir Med 97 7 2003 Jul 844 850
116. H. Nakamura, S. Fujishima, T. Inoue, Y. Ohkubo, K. Soejima, and Y. Waki Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection Eur Respir J 13 6 1999 Jun 1371 1379
117. H. Kobayashi, H. Takeda, S. Sakayori, Y. Kawakami, Y. Otsuka, and M. Tamura Study on azithromycin in treatment of diffuse panbronchiolitis Kansenshogaku Zasshi 69 6 1995 Jun 711 722
118. M. Akira, T. Higashihara, M. Sakatani, and H. Hara Diffuse panbronchiolitis: follow-up CT examination Radiology 189 2 1993 Nov 559 562
119. A. Boehler, S. Kesten, W. Weder, and R. Speich Bronchiolitis obliterans after lung transplantation: a review Chest 114 5 1998 Nov 1411 1426
120. T. Ishii, A. Manabe, Y. Ebihara, T. Ueda, H. Yoshino, and T. Mitsui Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin Bone Marrow Transplant 26 8 2000 Oct 907 910
121. K. Bando, I.L. Paradis, S. Similo, H. Konishi, K. Komatsu, and T.G. Zullo Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management J Thorac Cardiovasc Surg 110 1 1995 Jul 4 13 [discussion -4]
122. S.G. Gerhardt, J.F. McDyer, R.E. Girgis, J.V. Conte, S.C. Yang, and J.B. Orens Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study Am J Respir Crit Care Med 168 1 2003 Jul 1 121 125
123. G.M. Verleden, and L.J. Dupont Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation Transplantation 77 9 2004 May 15 1465 1467
124. G.M. Verleden, B.M. Vanaudenaerde, L.J. Dupont, and D.E. Van Raemdonck Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome Am J Respir Crit Care Med 174 5 2006 Sep 1 566 570
125. D. Shitrit, D. Bendayan, S. Gidon, M. Saute, I. Bakal, and M.R. Kramer Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients J Heart Lung Transplant 24 9 2005 Sep 1440 1443
126. B. Yates, D.M. Murphy, I.A. Forrest, C. Ward, R.M. Rutherford, and A.J. Fisher Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome Am J Respir Crit Care Med 172 6 2005 Sep 15 772 775
127. L.F. Angel, D. Levine, J. Sanchez, and S. Levine Azithromycin in bronchiolitis obliterans: is the evidence strong enough? Am J Respir Crit Care Med 173 4 2006 Feb 15 465 466 [author reply 6]
128. J. Gottlieb, J. Szangolies, T. Koehnlein, H. Golpon, A. Simon, and T. Welte Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation Transplantation 85 1 2008 Jan 15 36 41
129. T.C. Kotsimbos, G.I. Snell, B. Levvey, D.W. Spelman, A.J. Fuller, and S.L. Wesselingh Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation Transplantation 79 3 2005 Feb 15 269 275
130. A.R. Glanville, M. Gencay, M. Tamm, P. Chhajed, M. Plit, and P. Hopkins Chlamydia pneumoniae infection after lung transplantation J Heart Lung Transplant 24 2 2005 Feb 131 136
131. J.M. Zuckerman Macrolides and ketolides: azithromycin, clarithromycin, telithromycin Infect Dis Clin North Am 18 3 2004 Sep 621 649 [xi-]
132. E.B. Wilms, D.J. Touw, and H.G. Heijerman Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis Ther Drug Monit 28 2 2006 Apr 219 225
133. F. Scaglione, and G. Rossoni Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin J Antimicrob Chemother 41 Suppl. B 1998 Mar 47 50
134. M. Yamamoto, A. Kondo, M. Tamura, T. Izumi, Y. Ina, and M. Noda Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis Nihon Kyobu Shikkan Gakkai Zasshi 28 10 1990 Oct 1305 1313